---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-21-000296"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:22:42.374848+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q2 revenue $251M (+68.6% YoY); raises FY2021 guidance to $950M sales, $1.89-2.00 EPS

## Summary
- Q2 worldwide net sales of $251.0M, up 68.6% YoY; GAAP net income $41.5M (16.6% of sales), up 299.4% YoY.
- GAAP diluted EPS $0.40, Non-GAAP diluted EPS $0.56, compared to ($0.21) and $0.07 in Q2 2020 respectively.
- U.S. Spine business grew ~64% YoY; Enabling Technologies revenue $21M (nearly 4x Q2 2020).
- Raised FY2021 guidance: net sales to $950M (from $925M) and non-GAAP diluted EPS to $1.89-$2.00.
- Cash and marketable securities $914.2M, no debt; generated $59.2M operating cash flow, $50.8M free cash flow in Q2.

## SEC filing metadata
- accession: 0001562762-21-000296
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276221000296/0001562762-21-000296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276221000296/gmed-20210804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-21-000296
- JSON: https://secwatch.observer/filing/0001562762-21-000296.json
- Plain text: https://secwatch.observer/filing/0001562762-21-000296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.